These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37655551)

  • 1. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Tepper SJ; Schwedt TJ; Vo P; Thompson J; Joshi P; Abdrabboh A; Ferraris M; Tiwari S
    Headache; 2023; 63(10):1423-1436. PubMed ID: 37655551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.
    Urman R; Princic N; Vuvu F; Patel LB; Oh S; Chandler D; Hindiyeh N; Bensink ME
    Pain Ther; 2024 Oct; 13(5):1299-1313. PubMed ID: 39177937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
    Tepper SJ; Fang J; Vo P; Shen Y; Zhou L; Abdrabboh A; Glassberg M; Ferraris M
    J Headache Pain; 2021 Apr; 22(1):27. PubMed ID: 33874884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.
    Chandler D; Szekely C; Aggarwal S; Cyprien L; Bensink M
    Pain Ther; 2021 Dec; 10(2):1551-1566. PubMed ID: 34533779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis.
    Fang J; Korrer S; Johnson JC; Cheadle MA; Shah R; Ferraris ML; Lopez-Lopez C
    Adv Ther; 2021 Jun; 38(6):2921-2934. PubMed ID: 33763828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource utilization impact of topiramate for migraine prevention in the managed-care setting.
    Wertz DA; Quimbo RM; Yaldo AZ; Rupnow MF
    Curr Med Res Opin; 2009 Feb; 25(2):499-503. PubMed ID: 19192995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
    McAllister P; Lamerato L; Krasenbaum LJ; Cohen JM; Tangirala K; Thompson S; Driessen M; Casciano J; Dotiwala Z; Mauskop A
    J Headache Pain; 2021 Dec; 22(1):156. PubMed ID: 34930112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M; Benner J; Neumann P; Menzin J
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.